Herantis Pharma Oyj
HRPMF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $2 | $1 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3 | $1 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$0 | -$5 | -$0 |
| Operating Expenses | $2 | $3 | -$3 | $2 |
| Operating Income | -$2 | -$3 | $3 | -$2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$1 |
| Pre-Tax Income | -$2 | -$3 | $2 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$3 | $1 | -$1 |
| % Margin | – | – | – | – |
| EPS | -0.11 | -0.13 | 0.059 | -0.053 |
| % Growth | 15.4% | -318.9% | 211.9% | – |
| EPS Diluted | -0.11 | -0.13 | 0.059 | -0.053 |
| Weighted Avg Shares Out | 20 | 20 | 17 | 17 |
| Weighted Avg Shares Out Dil | 20 | 20 | 17 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | -$1 | $1 |
| EBITDA | -$2 | -$5 | $1 | -$1 |
| % Margin | – | – | – | – |